Innvierte spent in july and august 126.5 billion 13 new coinversiones in risk capital and 1 vehicle

The CDTI Innovation, sponsor and sole shareholder of society Innvierte, has closed, in the past few months of july and august, 13 joint investment operations, including 2 strategic, amounting to €53.086.000, in particular:

• ABILITY PHARMACEUTICALS, S.A.(Barcelona) is a biopharmaceutical company research and development of innovative oral drug treatment for cancer, based on autophagy as new therapeutic strategy to induce selective killing cancer cells. The investment is done with Inveready Biotech III SCR, S.A., Inveready Biotech III Parallel SCR, S.A., Pioneers Emporion SCR S.A., CTI Life Sciences Fund III LP and STI Life Science Fund III (International) LP and the input of CDTI Innovation is 720 euros.

• ALLOSTERY EXPLORATION TECHNOLOGIES, S.L. (ALLOX)(Barcelona) develops a technology platform, which combines biology and computer technology, to identify sites in protein alostéricos relevant to the treatment of cancer and other diseases through the development of new drugs. The investment is done with Sabadell Asabys Health Innovation Investments II, RCF and Sabadell Asabys Health Innovation Investments 2B, SCR S.A. and the input of Innovation is of CDTI 1.066.000 euros.

• DENEB MEDICAL, S.L.(Donostia) develops a platform for robotic surgery surgical backbone. Investment is done with EASO VENTURES II, SCR S.A. and the input of CDTI Innovation is €225,000.

• HONEXT MATERIALS, S.L. (HONEXT)(Barcelona) has developed an innovative industrial biotechnology process that transforms raw sewage of paper pulp boards circulars to the construction of interiors. The removable HONEXT ® ️, certified as circular, fire-resistant and carbon footprint refusal, represent a new generation of materials for construction, aligned with the principles of the circular economy and the decarbonisation of the sector. The investment is done with P.SAS PONT, S.L. and the input of CDTI Innovation is 3.33 million worth of euros, designed to accelerate the development and industrialization of this unique technology in europe.

• INTEGRATES PHARMACEUTICALS S.L.(Barcelona) develops a platform of gene edition for the treatment of oncology diseases, immune and genetic in origin. The investment is done with INVIVO VENTURES, RCF, COLUMBUS LIFE SCIENCES FUND III, F.C.R. and AdBio Partners AFB SEED-FUND II and the contribution of CDTI Innovation is 2.7 million euros.

• MIMARK DIAGNOSTICS, S.L.(Barcelona) develops WomEC, a test of in vitro diagnosis (IVD) for the diagnosis of The Uterus cancer (EC), based on the quantification of protein biomarkers present in the soluble fraction of the fluid and cervical cancer; Investment is done with NARA HEALTH CAPITAL I, F.C.R., INVEREADY BIOTECH IV SCR SA and INVEREADY BIOTECH IV PARALLEL, SCR, S.A. and the input of Innovation is of CDTI 333,000 euros.

• NÉBODA FARMS, S.L.(Pontevedra) is devoted to agriculture sustainable internal vertical. With a value proposition is based on the development of technology and a sound scientific know-how, presently producing sheet vegetables and herbs of high added value. The objective of the round is the optimization of industrial plant and the preparation of the company to undertake the production of an industrial plant 1,800 square metres, with investment PROMOTION FUND MONDRAGON II and UNIRISCO GALICIA, S.C.R., S.A. and the input of CDTI Innovation is 500,000 euros.

• ONA PHARMACEUTICALS, S.L.(Barcelona) is a dedicated biotech to transform the treatment of cancer advanced refractory and through the development of new innovative therapies using ADCs (Anticuerpo-Conjugado of drug). Investment is done with SABADELL ASABYS HEALTH INNOVATION INVESTMENTS, S.C.R., S.A., ASABYS TOP UP FUND, RCF, YSIOS BIOFUND III, FCRE, HIGH LIFE SCIENCES SPAIN I RCF and FUNDPLUS NV and the contribution of CDTI Innovation is eur 10,000,000.

• ONCOSTELLAE S.L.(Santiago de Compostela) develops medicines for treatment of diseases with unmet medical needs in the area of immunology and women's health. The investment is done with Bio & Tech Smart Capital, FCRE, Inveready Civilon BI, SCR, SA (previously named Inveready Innvierte Biotec II, SCR SA) and Unirisco Galicia, SCR, SA., and the input of Innovation is CDTI 279 euros.

• X1 WIND (Roughly Exponential Renewables S.L.)(Barcelona), develops a floating wind system proved innovative and ready to change the paradigm of offshore wind industry investment is done with CLUB RG 14, S.L. and the input of CDTI 405,000 is Innovation.

• 011H SUSTAINABLE CONSTRUCTION S.L. (011H)(Barcelona), within the digitization of the construction sector, has designed a platform addressed to the design and construction of buildings. The investment is done with SEAYA ANDROMEDA SUSTAINABLE TECH FUND I RCF REDALPINE CAPITAL, SCS, SYCHAR (investor french), BREEGA VENTURE II (luxembourg investor), BSOCIAL IMPACT FUND, FESE, S.A. and BSOCIAL IMPACT FUND II FESE, S.A.; and the input of Innovation is of CDTI 5.436.000 euros.

In addition, in line with strategic enterprises, the CDTI innovation has committed €17.249.000 companyPAYLOAD AEROSPACE, S.L.(Alicante), which develops technologies for the launch of small satellites; and 10.843.000 euros in the companyXOOPLE, S.L.(Madrid), which provides satellite Remote Sensing-based own GlobalEye constellation.

Since january 2025 the CDTI Innovation through Innvierte has closed operations, joint investment in 48 enterprises with a commitment of $120.6 million euros, and has closed investments in 6 investment vehicles with a commitment of $651 million euros.

Investment vehicles:

In addition, during the past few months of july and august, the CDTI Innovation, through Innvierte, committed investments in an investment vehicle in the amount of €73.500.000. In particular:

• KIBO VENTURES FUND IV INNVIERTE FCRE,managed by KIBO VENTURES PARTNERS, SGEIC, S.A. (Madrid), will invest in software companies with technologies spreads and ability to climb globally. The fund will focus especially on business cyber DeepTech as artificial intelligence, robotics, climate, health, education and other disruptive technologies. The commitment of the CDTI Innovation is 73.500.000 euros. Kibo Ventures has funded early many major spanish startups as Flywire (IPO Nasdaq), Devo, JobandTalent, Vilynx (learned by Apple) and Onum (acquired by CrowdStrike).

Innvierte

Innvierte is an initiative aimed at promoting the entrepreneurial innovation through support to the risk capital investment in technology-based enterprises or innovative programme. This is done through the collective investment type closed Innvierte Sustainable Economy SICC S.M.E., S.A., self-managed and under the supervision of the national Values and that the CDTI Innovation is a shareholder Only.

To date, the CDTI innovation has committed 2,661 M €in 61 investment vehicles that have invested in more than 622 companies, and through its joint investment line directly committed an amount of 723 M €in 190 firms.

Innvierte fits into the strategy for science, technology and innovation 2021-2027, adopted by decision of the council of ministers, in september. This 2020 Strategy contains goals, the reforms and measures to be taken throughout the area of r + D + i in order to boost their growth and impact, and is one of the pillars on which the design of the government's policy in r + D + i for the coming years.

CDTI Innovation

The centre for technological development and innovation, CDTI E.P.E. is the agency for innovation of the ministry of science, innovation and universities, whose goal is the promotion of technological innovation in business. The CDTI mission is to ensure that the business fabric english generates and transform knowledge into growth científico-técnico globally competitive, sustainable and inclusive. By 2024, within the framework of a new strategic plan, the CDTI provided more than $2.3 billion euros of support for business startups and spain.

You can consult the conditions of aid under the CDTI Innovation on the web page:www.cdti.es.

More information:

Office of the press
prensa@cdti.es
91-581.55.00

On The Internet
Website:www.cdti.es
In LinkedIn:https :// www.linkedin.com/company/cdti/
X:https :// twitter.com/CDTI _ innovation
On YouTube:https :// www.youtube.com/user/CDTIoficial

This content is copyright © 2025 CDTI, Soes. Permitted for use and reproduction by quoting the source and digital identity of CDTI (@CDTI _ innovation).